Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can Axovant's RVT-1 Redeem 5HT6 Class After Lundbeck's Idalopirdine Failure?

Feb 09 2017

• By Emily Hayes

Human brain illustrated with millions of small nerves - Conceptual 3d render

Related Content

Lundbeck's Alzheimer's Strategy Targets Symptoms And Disease Modification

Aug 22 2016

Full Monty On Pfizer’s Failed 5-HT6 Alzheimer’s Drug Leaves Hope For Class

Jul 26 2016

Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test

Sep 23 2016

Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success

Nov 23 2016

Related Companies

H. Lundbeck A/S

Otsuka Holdings Co., Ltd.

Sio Gene Therapies, Inc.

Pfizer Inc.

Sio Gene Therapies, Inc.

Suven Life Sciences Ltd.

Eli Lilly and Company

Additional Topics

Clinical Trials Research & Development Neurology BioPharmaceutical

More from Neurological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window